Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | CD74 | P04233 | 1/20 | 0.54 |
| ▸ | MIF | P14174 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | BLVRB | P30043 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59719 | 0.85 | MAOA (0.64) | KEAP1CD74MIFKMOL3MBTL1 | |
| SCHEMBL9848178 | 0.81 | CYP1A2 (0.50) | KEAP1CD74MIFL3MBTL1POLB | |
| SCHEMBL2710232 | 0.80 | CD74 (0.42) | KEAP1CD74MIFKMOMAOA | |
| SCHEMBL9848195 | 0.78 | TP53 (0.58) | POLBALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL30725957 | 0.75 | KMO (0.86) | KEAP1CD74MIFKMORXRA | |
| SCHEMBL71238 | 0.75 | KMO (0.86) | KEAP1CD74MIFKMORXRA | |
| SCHEMBL29904709 | 0.75 | KMO (0.86) | KEAP1CD74MIFKMORXRA | |
| SCHEMBL27103110 | 0.74 | PTPN1 (0.55) | KEAP1KMOL3MBTL1POLBKDM4E | |
| SCHEMBL30782369 | 0.74 | PTPN1 (0.55) | KEAP1KMOL3MBTL1POLBKDM4E | |
| SCHEMBL2975591 | 0.74 | DHODH (0.51) | POLBKDM4EALDH1A1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-8933109-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8552202-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8389737-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2297162-B1 | COMPOUNDS | AMURA THERAPEUTICS LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2283022-B1 | FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-07-18 | — | — | EP | disclosed |
| WO-2009112839-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KEAP1 3654/4885CD74 1040/4885MIF 984/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KEAP1 3543/4885CD74 830/4885MIF 1358/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KEAP1 3654/4885CD74 1040/4885MIF 984/4885 |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KEAP1 3654/4885CD74 1040/4885MIF 984/4885 |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KEAP1 3654/4885CD74 1040/4885MIF 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.